BioNTech SE
Q3 2022 Earnings Call
Nov 07, 2022, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Welcome to the BioNTech third quarter 2022 update call. I would like to hand the call over to the vice president of investor relations and strategy, Sylke Maas. Please go ahead, Sylke.
Sylke Maas -- Vice President, Investor Relations
Thank you all for joining us today as we review our third quarter operational highlights and provide you with a financial update. BioNTech is in an exciting phase of its corporate development, and we are delighted to share our progress with you. A few housekeeping items before we start. I invite you to view the slides that accompany the webcast and the third quarter 2022 press release, both of which were issued this morning and can be found in the investor section of our website.
Taking a first look at Slide 2, I would like to remind you that during today's presentation, we will make several forward-looking statements. These forward-looking statements include but are not limited to our COVID-19 vaccine revenues as these include figures that are derived from preliminary estimates provided by our partners; our estimated financial results for 2022; the continued global demand for our COVID-19 vaccine; expected COVID-19 vaccine production, supply, and deliveries for 2022 and beyond; the planned next steps in our pipeline programs; the timing for enrollment, initiation, completion, and reporting of data from our clinical trials; the timing of and our ability to obtain and maintain regulatory approval for our product candidates; and other risks described in our filings made with the U.S. Securities and Exchange Commission, including our most recent quarterly report filed today. Actual results could differ from those we currently anticipate.
You are, therefore, cautioned not to place undue reliance on any forward-looking statements, which speak only as of today, share today during the conference call and webcast. Also, please note that Slides 3 and 4 provide detailed and important safety information regarding our COVID-19 vaccine. Finally, today's agenda can be found on Slide 5. It is my pleasure to welcome the BioNTech management team, who will guide you through our third quarter update.
I'm joined by Uğur Şahin, CEO and co-founder of BioNTech; Ozlem Tureci, our chief medical officer and co-founder; Jens Holstein, our chief financial officer; and Ryan Richardson, our chief strategy officer. With that, I would like to turn the call over to Ugur.